noncontiguous stage II adult diffuse mixed cell lymphoma
Showing 1 - 25 of >10,000
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +71 more
- lenalidomide
- +8 more
-
Chicago, Illinois
- +5 more
Oct 8, 2021
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Terminated
- Adult Grade III Lymphomatoid Granulomatosis
- +116 more
- brentuximab vedotin
- +2 more
-
Chicago, Illinois
- +2 more
Aug 30, 2021
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma
Completed
- Adult Grade III Lymphomatoid Granulomatosis
- +88 more
- bortezomib
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Apr 14, 2021
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Completed
- Hematopoietic/Lymphoid Cancer
- +135 more
- beclomethasone dipropionate
- +4 more
-
Hackensack, New Jersey
- +1 more
Feb 1, 2021
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia
- +125 more
- tetanus-CMV fusion peptide vaccine
- laboratory biomarker analysis
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 28, 2022
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2
Active, not recruiting
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
- +22 more
- External Beam Radiation Therapy
- Orbital Radiation
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell
Completed
- AIDS-related Diffuse Large Cell Lymphoma
- +8 more
- cyclophosphamide
- +7 more
-
Eldoret, Kenya
- +1 more
Sep 12, 2022
Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene
Not yet recruiting
- Lymphoma, Large B-Cell, Diffuse
- +3 more
- Relmacabtagene Autoleucel
- +2 more
-
Guangzhou, Guangdong, China
- +12 more
Oct 24, 2023
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +23 more
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
DLBCL (DLBCL) Trial (Tisagenlecleucel)
Withdrawn
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Tisagenlecleucel
- (no location specified)
Feb 25, 2022
Lymphoma, Non-Hodgkin's, Adult Trial in Rosario, Caba (Evaluation of first line treatment in patients with stage I and II LBCL)
Recruiting
- Lymphoma, Non-Hodgkin's, Adult
- Evaluation of first line treatment in patients with stage I and II LBCL
-
Paraná, Entre Ríos, Argentina
- +6 more
Dec 29, 2022
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic
Completed
- Accelerated Phase Chronic Myelogenous Leukemia
- +99 more
- fludarabine phosphate
- +4 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 30, 2019
Chronic Myeloproliferative Disorders, GVHD, Leukemia Trial in Buffalo (sargramostim)
Completed
- Chronic Myeloproliferative Disorders
- +5 more
- sargramostim
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 3, 2022
Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult
Completed
- Contiguous Stage II Adult Lymphoblastic Lymphoma
- +5 more
- carfilzomib
- +10 more
-
Sacramento, CaliforniaUniversity of California Davis
Mar 8, 2022
Lymphoma Trial in Scottsdale, Jacksonville, Rochester (biological, drug, genetic, other)
Active, not recruiting
- Lymphoma
- pegfilgrastim
- +8 more
-
Scottsdale, Arizona
- +2 more
Jan 7, 2022
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma Trial in
Completed
- Contiguous Stage II Mantle Cell Lymphoma
- +5 more
- bortezomib
- +9 more
-
Duarte, California
- +1 more
Jan 12, 2022
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in
Completed
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +20 more
- panobinostat
- +6 more
-
Scottsdale, Arizona
- +1 more
May 6, 2022
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular
Recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- +19 more
- CD47 Antagonist ALX148
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,
Recruiting
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Scottsdale, Arizona
- +2 more
Jun 1, 2022
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 18, 2022
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid
Completed
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- +99 more
- alemtuzumab
- +6 more
-
Denver, Colorado
- +6 more
Jan 15, 2020
Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory DLBCL Trial in Canada (DPX-Survivac, Pembrolizumab,
Active, not recruiting
- Adult Diffuse Large Cell Lymphoma
- +2 more
- DPX-Survivac
- +2 more
-
Calgary, Alberta, Canada
- +5 more
Nov 9, 2022
CD20 Positive, Recurrent DLBCL, Refractory DLBCL Trial in Buffalo (drug, other, biological)
Active, not recruiting
- CD20 Positive
- +6 more
- Carboplatin
- +6 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 11, 2021
GVHD, Leukemia, Lymphoma Trial in Duarte (biological, drug, procedure, radiation, other)
Active, not recruiting
- Graft Versus Host Disease
- +2 more
- rituximab
- +8 more
-
Duarte, CaliforniaCity of Hope Medical Center
Mar 17, 2022